One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Headway and hurdles in non-alcoholic fatty liver disease
doi : 10.1016/S2468-1253(19)30429-7
Volume 5, Issue 2, February 2020, Page 93
Traditional treatments for irritable bowel syndrome: the state of our knowledge
HansTörnbloma
High-dose NSAIDs and pancreatitis after ERCP: more is not always better
Surinder SinghRanaa
Minimally invasive gastrectomy: time to change practice?
FelixBerlthaPeter PhilippGrimmingera
Core inhibitor therapy for chronic hepatitis B
Milan JSonnevelda
Sustain, accelerate, innovate: the burden of liver disease and way forward in the WHO South-East Asia region
Poonam KhetrapalSingha
Time to act to make elimination of viral hepatitis a reality
TakeshiKasaia
How many deaths are caused by non-alcoholic fatty liver disease in the Asia-Pacific region?
Grace Lai-HungWongabVincent Wai-SunWongab
Restricting alcohol consumption to reduce liver disease in the Asia-Pacific region
HengJiangabRobinRoomacOrrataiWaleewongdWeiHaoef
Communities living with hepatitis must be central to the response to liver diseases in the Asia-Pacific region
ChrisWingroveaSuWangabcMichaelNinburgadEdoAgustianaeDeeLeeaf
Polyethylene glycol-based laxatives for chronic constipation
FatmaAkricheaBharatAmlaniaJonathanBelseyb
Polyethylene glycol-based laxatives for chronic constipation – Authors' reply
PavitLuthraaMichaelCamilleribNicholas EBurrcdEamonn M MQuigleyeChristopher JBlackcdAlexander CFordcd
Efficacy of soluble fibre, antispasmodic drugs, and gut–brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis
Christopher JBlackMBBSabYuhongYuanPhDcChristian PSelingerMDaProfMichaelCamilleriMDdProfEamonn M MQuigleyMDeProfPaulMoayyediPhDcProfAlexander CFordMDab
Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial
ProfEvan LFogelMDaProfGlen ALehmanMDaPaulTarnaskyMDbProfGregory ACoteMDcSuzette ESchmidtRNaAkbar KWaljeeMDdProfPeter D RHigginsMDdJames LWatkinsMDaProfStuartShermanMDaRichard S YKwonMDdProfGrace HEltaMDdJeffrey JEaslerMDaDouglas KPleskowMDeProfJames MScheimanMDfIhab IEl HajjMDagProfNalini MGudaMDhiMark AGromskiMDaProfLeeMcHenryJrMDa…ProfB JosephElmunzerMDc
Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial
ProfHitoshiKataiMDaJunkiMizusawaMEbHiroshiKatayamaMDbShinjiMoritaMDaTakanobuYamadaMDcEtsuroBandoMDdSeijiItoMDeMasakazuTakagiMDfAkinoriTakaganeMDgShinTeshimaMDhKeisukeKoedaMDiSouyaNunobeMDjTakakiYoshikawaMDaMasanoriTerashimaMDdProfMitsuruSasakoMDk
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
ProfMan-FungYuenDScaKoshAgarwalMDbProfEdward JGaneMDcChristianSchwabeMDcSang HoonAhnMDdProfDong JoonKimPhDeProfYoung-SukLimMDfProfWendyChengMDgProfWilliamSievertMDhProfKumarVisvanathanPhDiEricRubyMSjSandyLiawBAjRanYanPhDjQiHuangPhDjRichardColonnoPhDjUriLopatinMDj
Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission
ProfShiv KSarinDMaProfManojKumarDMaMohammedEslamMDbProfJacobGeorgeFRACPbMamunAl MahtabMDcSheikh M FazleAkbarPhDdProfJidongJiaMDeQiujuTianMDeProfRakeshAggarwalDMfProfDavid HMuljonoMDgProfMasaoOmataMDhiYoshihikoOokaMDjProfKwang-HyubHanMDkHye WonLeeMDkProfWasimJafriFRCPlAmna SButtMDlChern HChongMRCPmnProfSeng GLimFRCPmo…ProfDing-ShinnChenMDqr
